Xeris Biopharma, Inc.

154 articles with Xeris Biopharma, Inc.

• Xeris Biopharma Announces Gvoke® Kit Is Now Available for the Treatment of Severe Hypoglycemia in Adults and Children With Diabetes Ages 2 And Above

  3/16/2022

  Xeris Biopharma Holdings, Inc. today announced that Gvoke® (glucagon injection) Kit is now available by prescription.

• Xeris Announces $150M Senior Secured Term Loan Facility With Hayfin Capital

  3/10/2022

  Xeris Biopharma Holdings, Inc. today announced it has entered into a senior secured term loan agreement (“debt facility”) with funds managed by Hayfin Capital Management LLP (“Hayfin”) to provide Xeris with up to a total of $150 million of capital.

• Xeris Biopharma Reports Fourth Quarter and Full-year 2021 Financial Results and Recent Events

  3/10/2022

  Xeris Biopharma Holdings, Inc. today announced financial results for the fourth quarter and full-year 2021 and recent highlights.

• Xeris Biopharma to Report Fourth Quarter and Full Year 2021 Financial Results on March 10, 2022

  3/4/2022

  Xeris Biopharma Holdings, Inc. today announced that the Company will release its fourth quarter and full year 2021 financial results before the open of the U.S. financial markets on Thursday, March 10, 2022.

• Xeris Biopharma to Participate in the 11th Annual SVB Leerink Global Healthcare Conference

  2/9/2022

  Xeris Biopharma to Participate in the 11th Annual SVB Leerink Global Healthcare Conference.

•  Xeris Biopharma Reaffirms 2021 Guidance and Provides Business Update

  1/18/2022

  Xeris Biopharma Reaffirms 2021 Guidance and Provides Business Update.  

• Xeris Biopharma to Participate in H.C. Wainwright BioConnect 2022 Virtual Conference

  1/6/2022

  Xeris Biopharma Holdings announced that Paul R. Edick, Chairman and Chief Executive Officer of Xeris Biopharma, will present an overview of the company and highlight recent events, including the FDA approval of Recorlev®, at the H.C. Wainwright BioConnect 2022 virtual conference being held January 10-13, 2022.

• Xeris Biopharma Enters Into Agreement for $30 Million Private Placement

  1/3/2022

  Xeris Biopharma Holdings, Inc. today announced that on January 2, 2022, it entered into a securities purchase agreement in connection with a private placement (the “Private Placement”) with an affiliate of Armistice Capital, LLC.

• Xeris Biopharma Announces the Availability of Ogluo® in the UK Through Its Commercialization Partner, Tetris Pharma

  12/16/2021

  Xeris Biopharma Holdings, Inc. today announced that its commercialization partner, Tetris Pharma (Tetris), has launched Ogluo® (glucagon injection) in the United Kingdom and it is now available by prescription for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus.

• Xeris Biopharma Reports Third Quarter 2021 Financial Results and Other Highlights

  11/10/2021

  Xeris Biopharma Holdings, Inc. today announced financial results for the third quarter and first nine months ended September 30, 2021, and recent highlights, including the completion of the Strongbridge Biopharma plc acquisition on October 5, 2021.

• Xeris Biopharma to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 10, 2021

  11/2/2021

  Xeris Biopharma Holdings, Inc. today announced that the Company will release its third quarter 2021 financial results before the open of the U.S. financial markets on Wednesday, November 10, 2021.

• Xeris Pharmaceuticals Enters Collaboration Agreement With Merck

  10/25/2021

  Xeris Biopharma Holdings, Inc. today announced a collaboration agreement with Merck, with an option to license Xeris’ suspension-based formulation technology, XeriJect™

• 

  Feeling Collaborative, Merck Inks Three More Deals to Strengthen Portfolio

  10/25/2021

  Merck entered into collaborations with three different companies as it continues to assess Keytruda in combination with experimental drugs in different cancer indications.

• Xeris Pharmaceuticals Completes Acquisition of Strongbridge Biopharma

  10/5/2021

  Xeris Pharmaceuticals, Inc. (“Xeris”), a pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable drug formulations, today announced that it has successfully completed the previously announced acquisition of Strongbridge Biopharma plc (Nasdaq: SBBP) (“Strongbridge”).

• Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Oct 01, 2021

  10/1/2021

  Xeris Pharmaceuticals, Inc. announced that on October 1, 2021, the Compensation Committee of Xeris’ Board of Directors granted restricted stock units for an aggregate of 28,750 shares of its common stock to 20 new employee under Xeris’ Inducement Equity Plan.

• Xeris Pharmaceuticals to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

  9/17/2021

  Xeris Pharmaceuticals, Inc. today announced that Paul R. Edick, Chairman and Chief Executive Officer of Xeris Pharmaceuticals, will present an overview of the Company at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on Wednesday, September 22, 2021

• Xeris Pharmaceuticals Stockholders Approve Acquisition of Strongbridge Biopharma

  9/14/2021

  Xeris Pharmaceuticals, Inc. (Nasdaq: XERS) (“Xeris”) today announced that its stockholders have voted to approve the previously announced proposed acquisition of Strongbridge Biopharma plc (NASDAQ: SBBP) (“Strongbridge”) by Xeris.

• Strongbridge Biopharma plc Announces Shareholder Approval of Proposed Acquisition by Xeris Pharmaceuticals, Inc.

  9/8/2021

  Strongbridge Biopharma plc announced that its shareholders have voted to approve the previously announced proposed acquisition of Strongbridge by Xeris Pharmaceuticals, Inc. .

• Xeris Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

  9/7/2021

  Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that Paul R. Edick, Chairman and Chief Executive Officer of Xeris Pharmaceuticals, will present an overview of the Company during the H.C. Wainwright 23rd Annual Global Investment Conference.

• Xeris Pharmaceuticals Completes Enrollment of Its Phase 1 Study of Levothyroxine (XP-8121)

  9/1/2021

  Xeris Pharmaceuticals, Inc. today announced that the company has completed enrollment and successfully dosed all participants in a Phase 1 study of levothyroxine (XP-8121) to evaluate the pharmacokinetics, safety and tolerability, and potential for weekly dosing of the investigational, novel, subcutaneous (SC) injection for the treatment of hypothyroidism.